Gestational Trophoblastic Disease: Statistics

Approved by the Cancer.Net Editorial Board, 01/2020

ON THIS PAGE: You will find information about the number of women who are diagnosed with GTD each year. You will also read general information on surviving the disease. Remember, survival rates depend on several factors. Use the menu to see other pages.

Overall, GTD is rare and often curable. In the United States, GTD accounts for less than 1% of all tumors that start in a woman's reproductive system, which is a grouping called gynecologic cancers. GTD occurs in about 1 out of every 1,000 pregnancies in the United States. Most of these are molar pregnancies. Choriocarcinoma occurs in about 2 to 7 pregnancies out of every 100,000 pregnancies in the United States. Overall, GTD is more common in other parts of the world, including Asia and Africa.

Nearly all women with a molar pregnancy or low-risk GTN can be cured, often using surgery alone that does not affect a woman’s fertility, which is her ability to have children. A PSTT can often be cured, particularly if it is found before it spreads outside the uterus. In 35% of women with PSTT, the cancer has already spread out of the uterus before it diagnosed. Even with faster-growing GTN, cure rates are as high as 80% to 90% with intensive treatment.

It is important to remember that statistics on the survival rates for women with GTD are an estimate. The estimate comes from annual data based on the number of women with GTD in the United States. Talk with your doctor if you have any questions about this information. Learn more about understanding statistics.

Statistics adapted from the American Cancer Society and the National Cancer Institute (websites accessed January 2020).

The next section in this guide is Medical Illustrations. It offers drawings of body parts often affected by GTD. Use the menu to choose a different section to read in this guide.